OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Burns on Key Advances Made in RET+ NSCLC

October 29th 2021

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

October 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Dr. Girard on the Next Steps With Durvalumab in NSCLC

October 29th 2021

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Dr. Dholaria on Patient Characteristics in the MagnetisMM-1 Trial in Multiple Myeloma

October 29th 2021

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Subramanian on the Current Standard of Care in Stage III NSCLC

October 29th 2021

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

October 28th 2021

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.

Dr. Venkat on Unmet Needs in Ovarian Cancer

October 28th 2021

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer.

Dr. Santos on Identifying Mechanisms of Resistance in Lung Cancer

October 28th 2021

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Dr. Cohen on the Safety Profile of Cilta-Cel in Multiple Myeloma

October 28th 2021

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

October 28th 2021

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

October 28th 2021

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Dr. Brown on the Utility of PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

October 27th 2021

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Brayer on the Promise of BiTEs in Multiple Myeloma

October 27th 2021

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

Dr. Simon on the Importance of Next-Generation Sequencing in NSCLC

October 27th 2021

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Dr. Raez on the Clinical Implications of the KEYNOTE-024 Trial in NSCLC

October 27th 2021

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Dr. Ku on Evaluating Zanidatamab Plus Chemotherapy in HER2-Expressing GEA

October 27th 2021

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Dr. Nguyen on Managing Mobocertinib-Related GI Toxicities in EGFR Exon 20 Insertion+ NSCLC

October 27th 2021

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Piccirillo on the Safety Profile of Bevacizumab Plus Erlotinib in EGFR+ Nonsquamous NSCLC

October 27th 2021

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Dr. Aguirre-Ghiso on Future Research Directions at Albert Einstein Cancer Center

October 27th 2021

Julio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.